Literature DB >> 618704

A psychological perspective for double-blind trials.

S M Zifferblatt, C S Wilbur.   

Abstract

Blind breaking is likely to occur in a long-term clinical trial involving subjects at risk. Double-blind conditions require subjects to live with ambiguity regarding their health status. It is unrealistic to expect them to tolerate this ambiguity over an extended period of time. A logical step for a subject is to break the blind and surreptitiously seek the best medical care available. Moreover, the staff assigned to monitor protocol adherence may further contribute to blind breaking because of ambiguity regarding their proper clinical role. Several steps are recommended to manage blind breaking within a trial, including improving the quality of medical care, more rigorous screening procedures, and maintaining a clinical environment that promotes accurate disclosure of blind breaking.

Mesh:

Year:  1978        PMID: 618704     DOI: 10.1002/cpt19782311

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  4 in total

1.  Quality of reports of clinical trials submitted by the drug industry to the Finnish and Swedish control authorities.

Authors:  E Hemminki
Journal:  Eur J Clin Pharmacol       Date:  1981-02       Impact factor: 2.953

2.  Informed consent and placebo effects: a content analysis of information leaflets to identify what clinical trial participants are told about placebos.

Authors:  Felicity L Bishop; Alison E M Adams; Ted J Kaptchuk; George T Lewith
Journal:  PLoS One       Date:  2012-06-27       Impact factor: 3.240

3.  Altruism, personal benefit, and anxieties: a phenomenological study of healthy volunteers' experiences in a placebo-controlled trial of duloxetine.

Authors:  Isaac N Kwakye; Matthew Garner; David S Baldwin; Susan Bamford; Verity Pinkney; Felicity L Bishop
Journal:  Hum Psychopharmacol       Date:  2016-07       Impact factor: 1.672

4.  A test of psychological and electrodermal changes immediately after the delivery of 3 analgesic treatment messages.

Authors:  Andrew L Geers; Stephanie L Fowler; Suzanne G Helfer; Ashley B Murray
Journal:  Pain Rep       Date:  2019-06-07
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.